Commentary on ‘Lymphovenous Microsurgical Shunts in Treatment of Lymphedema of Lower Limbs: A 45-year Experience of One Surgeon/One Center’  by Waltham, M.
INVITED COMMENTARYCommentary on ‘Lymphovenous Microsurgical Shunts in Treatment of
Lymphedema of Lower Limbs: A 45-year Experience of One Surgeon/One
Center’
M. Waltham *
King’s College London British Heart Foundation Centre of Research Excellence, Academic Surgery Department, St Thomas’ Hospital Campus, Westminster Bridge Road,
London, United KingdomLymphoedema remains a major health problem affecting
100e300 million people worldwide. In the developed
world, non-infective aetiologies predominate due to
primary (idiopathic) lymphoedema or as a consequence of
secondary damage to lymphatics following trauma,
surgery, or malignancy. For most patients with mild/
moderate lymphoedema, treatment involves compression
or massage therapies,1 although access to specialist
lymphatic services for investigation and appropriate
treatment varies widely.
Identiﬁcation of genetic causes of primary lymphoedema
has advanced signiﬁcantly over the last decade and
a number of surgical interventions are also enjoying
a revived interest. Focus has shifted towards renewed
attempts at enhancing drainage of lymph through ‘physi-
ological’ channels. From the earliest attempts by Handley
(who implanted subcutaneous silk threads in 19082), many
operations have tried to emulate physiological lymph
drainage, including skin and mesenteric bridges to bypass
obstructed segments. However, equivocal results
throughout the mid 20th century led to this approach
being supplanted by ‘excisional’ procedures such as
Homans’ reduction3 with good results being published by
some.4 Liposuction has also established a role in selected
patients.5
Edwards and Kinmonth demonstrated the existence of
lymphovenous shunts in lymphoedema patients in 19696
and operations to connect lymphatics to veins were pio-
neered from that time. Evidence for the efﬁcacy of these
treatments is, however, lacking. Many patients with primary
lymphoedema (whether sporadic or part of a recognised
hereditary genetic condition) have reduced or absent
functioning lymphatics throughout the affected limb and so
the therapeutic beneﬁt of forming lymphovenous shunts
must be questioned.
Professor Waldemar Olszewski has been a pioneer of this
technique, and in this issue of the European Journal of
Vascular and Endovascular Surgery, he presents data fromDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2012.11.025
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http://dx.doi.org/10.1016/j.ejvs.2013.01.001his 45-year experience of performing microsurgical lym-
phovenous shunts to treat lower limb lymphoedema.7
During this time-period, Professor Olszewski has treated
over 1300 patients with a range of lymphoedema aetiol-
ogies. The surgical technique involved anastomosis of either
inguinal node or dissected afferent lymphatics to the
saphenous vein or its tributaries. In comparison to other
contemporary series, Olszewski’s patient group had very
limited access to compression hosiery or other forms of
compression/massage therapy, suggesting that the pub-
lished results are unlikely to have been biased by these
adjuvant treatments.
The ﬁndings support the theoretical expectation that
primary hyperplastic and post-lymphadenectomy patients
beneﬁtted most from surgery, while those with post-
inﬂammatory damage or primary lymphoedema (hypo-
plastic, regressive or aplastic lymphatics) beneﬁtted least.
This study, therefore, emphasizes the importance of
identifying patients with primary lymphoedema who have
proximal iliac regression of lymphatics with preserved
distal vessels in order to maximise the beneﬁt of this type
of surgery. Where the underlying cause is more predict-
able (e.g. after inguinal dissection), there is a higher
likelihood of encountering functioning lymphatics in the
limb.
The future lies in the reﬁnement of these surgical tech-
niques, perhaps combined with adjuvant lymphangiogenic
therapy. Dedicated specialist centres providing a multidisci-
plinary approach to the treatment of lymphoedema and
other lymphatic diseases will provide the highest standard
of care and will permit full assessment of lymphatic func-
tion in order to identify potentially suitable patients.
Surgical treatments still have an important role in the
management of lymphoedema.REFERENCES
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